📊 Note: Daily ratings and analytics are updated after market close and will be available by 7:00 PM IST.

Details

NameSymbolSector
PIRAMAL PHARMA LIMITEDPPLPHARMAPharmaceuticals
Open
141.01
High
142.95
Low
136.05
Close
136.54
Volume
4589871
Exchange
nse
Time
30-Mar-2026

Outlook

Score:

1

Rating:

RISKY

Candlestick Pattern

CandlepatternofPiramalPharmais
Long Body
EstimatedStoplossofPiramalPharmais
142.95
PiramalPharmahasa
Bearishℹ
pattern.
Formationof
Long Body
candlepatternindicatesthetrenddirectionofPiramalPharmamaybe
Unpredictableℹ
,butkeepalookoutforfallinprice.

Trend

PiramalPharmaisin
Sideways trendℹ
.
PriceofPiramalPharmais
Downℹ
by

10.21

%.
Target
Buy@

134.34

Sell@

180.68

Current@

136.54

Volume

PiramalPharmahasseena
Significantℹ
riseinvolumeoftrades.
ThevolumetrendforPiramalPharmais
Bearishℹ
,buttheparticipantsare
Weak Sellersℹ
ThetradevolumeofPiramalPharmais

Up

by

37.98

%

Valuation

ThecurrentmarketpriceofPiramalPharmais
Undervaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth15677crandtotalassetsworth15677cr,thebalancesheetofPiramalPharmais:
Balancedℹ
.
Cashflow
PiramalPharmahas
Poorℹ
cashflowbecausethereis

Shortage

of

₹ 36cr

.Itis
Downℹ
by

121.82

%.
49.04% i.e. ₹ 892cr earned in operatingℹ
26.22% i.e. ₹ 477cr spent in investingℹ
24.19% i.e. ₹ 440cr spent in financingℹ
0.55% i.e. ₹ 10cr spent in otherℹ
PiramalPharmahas
Maintainedℹ
cashflowbecausethereis

Surplus

of

₹ 165cr

.Itis
Upℹ
by

632.26

%.
53.49% i.e. ₹ 1004cr earned in operatingℹ
23.12% i.e. ₹ 434cr spent in investingℹ
22.48% i.e. ₹ 422cr spent in financingℹ
0.91% i.e. ₹ 17cr earned in otherℹ
Income
TheincomeofPiramalPharmais

₹ 2109cr

and

Loss

is:

₹ 114cr

PiramalPharmaLossesincreasedby:

172.99

%andIncomeisDownby:

28.76

%
TheincomeofPiramalPharmais

₹ 1992cr

and

Profit

is:

₹ 100cr

PiramalPharmaProfitisupby:

1153.85

%andIncomeisUpby:

26.17

%
TheincomeofPiramalPharmais

₹ 2796cr

and

Loss

is:

₹ 137cr

PiramalPharmaLossesincreasedby:

360

%andIncomeisDownby:

3.74

%
By using this site you agree to the use of cookies to deliver a better site experience.